04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
20:30 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Other

INDICATION: Poisoning Mouse studies suggest a topical pyridine-2-aldoxime-based gel could help treat pesticide poisoning. The gel contains pyridine-2-aldoxime, which reverses binding and inactivation of AChE by pesticides, linked via an acetamide bridge to chitosan to...
17:32 , Oct 19, 2018 |  BC Week In Review  |  Company News

Gurnet to acquire Corium as it heads for NDA

Healthcare investor Gurnet Point Capital will acquire drug delivery company Corium International Inc. (NASDAQ:CORI) for $12.50 per share in cash plus $0.50 per share in a contingent value right (CVR). The deal, including the CVR,...
18:58 , Mar 29, 2018 |  BC Innovations  |  Emerging Company Profile

Strengthening synapses

Syndesi Therapeutics S.A. is developing SV2A modulators to improve cognitive function in a range of indications including mild-to-moderate Alzheimer’s disease by regulating a broader sweep of neurotransmitters than available therapies. Cognitive impairment in AD stems...
23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
19:06 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Biscayne reports Phase Ib data for epilepsy candidate BIS-001ER

Biscayne Neurotherapeutics Inc. (Miami, Fla.) reported data from a Phase Ib trial in 11 healthy volunteers showing that twice-daily 0.5-2.5 mg doses of epilepsy candidate BIS-001ER were well tolerated with no dose-limiting toxicities (DLTs) reported....
21:47 , Jul 21, 2017 |  BioCentury  |  Product Development

Surrogate start

Phase II results for Probiodrug AG ’s Alzheimer’s disease candidate point to potential surrogate markers for improvements in cognition that one day could be used in early development to handicap the likelihood of success in...
23:03 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other...
20:22 , Jun 13, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on ARHGAP15 and COLQ could help predict the risk of diverticular disease, and a SNP on FAM155A could help predict the risk of diverticulitis. Genome-wide association studies in 5,426 diverticular disease patients,...
21:20 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

Idalopirdine: Ph III STARBRIGHT data

Lundbeck said data from the double-blind, placebo-controlled, international Phase III STARBRIGHT trial in about 734 patients with mild to moderate AD who were on stable treatment with an acetylcholinesterase (AChE) inhibitor showed that oral idalopirdine...